PNAS:蛋白质互作模型或可以提供新的癌症疗法

2012-06-18 T.Shen 生物谷

近日,来自堪萨斯大学的研究者llya Vakser表示,蛋白质并不是多刚体(rigid bodies),它们可以改变形状并且非常灵活,因此我们常常可以将两个完全不匹配的蛋白质进行互相匹配。数年来,科学家依赖于计算机模型技术来表征蛋白质的特征,当然这种精确的计算机模型技术是基于通过X射线晶体学和核磁共振技术来对蛋白质的结构进行模板定位的。 直到现在,这种模板的实际应用价值对于蛋白-蛋白复合物是可用

近日,来自堪萨斯大学的研究者llya Vakser表示,蛋白质并不是多刚体(rigid bodies),它们可以改变形状并且非常灵活,因此我们常常可以将两个完全不匹配的蛋白质进行互相匹配。数年来,科学家依赖于计算机模型技术来表征蛋白质的特征,当然这种精确的计算机模型技术是基于通过X射线晶体学和核磁共振技术来对蛋白质的结构进行模板定位的。

直到现在,这种模板的实际应用价值对于蛋白-蛋白复合物是可用的。研究者发现了几乎完整的设置模型已经存在,这对于结构生物学来说意义深远,这意味未来某些疾病的新药研发提供一些线索。相关研究成果刊登在了国际著名杂志PNAS上。

对蛋白质互作很好的把握对于开发新药和通过改变蛋白质的行为而有利于人类健康治疗手段异常关键。研究者表示,你可以想象一下,蛋白质世界作用一个拥挤复杂的环境,在这种环境中,单一分子可以任意浮游着,而且可以进行互相碰撞;如果只是随机反应的话,并不会发生什么。但是如果单一分子有着生理学的重要性,他们就可能会互相依附,并且改变形状或者转移电子。

影响蛋白质之间互作的能力意味着新的疗法来治疗癌症和冠心病。这将给与我们足够的能力去模拟这些蛋白质的反应并且发现治疗疾病的路径。许多疾病都是由于蛋白质反应的异常情况所引起的,或者这种反应不被希望。但是通过药物来进行调节,我们需要知道其具体的作用原理和机制。本研究中,研究者提出了新的方法来影响蛋白质之间的相互作用,并且研究者后期会立即设计新的治疗手段来治疗某些疾病。

编译自:Research discovery: Near-complete set of templates for protein complexes exists today

编译者:T.Shen

doi:10.1073/pnas.1200678109
PMC:
PMID:

Templates are available to model nearly all complexes of structurally characterized proteins

Petras J. Kundrotasa, Zhengwei Zhub, Joël Janinc,1, and Ilya A. Vaksera,1

Traditional approaches to protein–protein docking sample the binding modes with no regard to similar experimentally determined structures (templates) of protein–protein complexes. Emerging template-based docking approaches utilize such similar complexes to determine the docking predictions. The docking problem assumes the knowledge of the participating proteins’ structures. Thus, it provides the possibility of aligning the structures of the proteins and the template complexes. The progress in the development of template-based docking and the vast experience in template-based modeling of individual proteins show that, generally, such approaches are more reliable than the free modeling. The key aspect of this modeling paradigm is the availability of the templates. The current common perception is that due to the difficulties in experimental structure determination of protein–protein complexes, the pool of docking templates is insignificant, and thus a broad application of template-based docking is possible only at some future time. The results of our large scale, systematic study show that, surprisingly, in spite of the limited number of protein–protein complexes in the Protein Data Bank, docking templates can be found for complexes representing almost all the known protein–protein interactions, provided the components themselves have a known structure or can be homology-built. About one-third of the templates are of good quality when they are compared to experimental structures in test sets extracted from the Protein Data Bank and would be useful starting points in modeling the complexes. This finding dramatically expands our ability to model protein interactions, and has far-reaching implications for the protein docking field in general.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1752891, encodeId=41a21e528919d, content=<a href='/topic/show?id=b103e1424b2' target=_blank style='color:#2F92EE;'>#癌症疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71424, encryptionId=b103e1424b2, topicName=癌症疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e236589107, createdName=mnda, createdTime=Sat Sep 08 20:52:00 CST 2012, time=2012-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765479, encodeId=87651e6547907, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Apr 15 01:52:00 CST 2013, time=2013-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855288, encodeId=0ea5185528890, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Nov 18 23:52:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296856, encodeId=ba181296856f5, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jun 20 09:52:00 CST 2012, time=2012-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471486, encodeId=567814e148690, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Jun 20 09:52:00 CST 2012, time=2012-06-20, status=1, ipAttribution=)]
    2012-09-08 mnda
  2. [GetPortalCommentsPageByObjectIdResponse(id=1752891, encodeId=41a21e528919d, content=<a href='/topic/show?id=b103e1424b2' target=_blank style='color:#2F92EE;'>#癌症疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71424, encryptionId=b103e1424b2, topicName=癌症疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e236589107, createdName=mnda, createdTime=Sat Sep 08 20:52:00 CST 2012, time=2012-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765479, encodeId=87651e6547907, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Apr 15 01:52:00 CST 2013, time=2013-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855288, encodeId=0ea5185528890, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Nov 18 23:52:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296856, encodeId=ba181296856f5, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jun 20 09:52:00 CST 2012, time=2012-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471486, encodeId=567814e148690, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Jun 20 09:52:00 CST 2012, time=2012-06-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1752891, encodeId=41a21e528919d, content=<a href='/topic/show?id=b103e1424b2' target=_blank style='color:#2F92EE;'>#癌症疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71424, encryptionId=b103e1424b2, topicName=癌症疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e236589107, createdName=mnda, createdTime=Sat Sep 08 20:52:00 CST 2012, time=2012-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765479, encodeId=87651e6547907, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Apr 15 01:52:00 CST 2013, time=2013-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855288, encodeId=0ea5185528890, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Nov 18 23:52:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296856, encodeId=ba181296856f5, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jun 20 09:52:00 CST 2012, time=2012-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471486, encodeId=567814e148690, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Jun 20 09:52:00 CST 2012, time=2012-06-20, status=1, ipAttribution=)]
    2012-11-18 drwjr
  4. [GetPortalCommentsPageByObjectIdResponse(id=1752891, encodeId=41a21e528919d, content=<a href='/topic/show?id=b103e1424b2' target=_blank style='color:#2F92EE;'>#癌症疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71424, encryptionId=b103e1424b2, topicName=癌症疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e236589107, createdName=mnda, createdTime=Sat Sep 08 20:52:00 CST 2012, time=2012-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765479, encodeId=87651e6547907, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Apr 15 01:52:00 CST 2013, time=2013-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855288, encodeId=0ea5185528890, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Nov 18 23:52:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296856, encodeId=ba181296856f5, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jun 20 09:52:00 CST 2012, time=2012-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471486, encodeId=567814e148690, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Jun 20 09:52:00 CST 2012, time=2012-06-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1752891, encodeId=41a21e528919d, content=<a href='/topic/show?id=b103e1424b2' target=_blank style='color:#2F92EE;'>#癌症疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71424, encryptionId=b103e1424b2, topicName=癌症疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e236589107, createdName=mnda, createdTime=Sat Sep 08 20:52:00 CST 2012, time=2012-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765479, encodeId=87651e6547907, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Apr 15 01:52:00 CST 2013, time=2013-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855288, encodeId=0ea5185528890, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Nov 18 23:52:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296856, encodeId=ba181296856f5, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jun 20 09:52:00 CST 2012, time=2012-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471486, encodeId=567814e148690, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Jun 20 09:52:00 CST 2012, time=2012-06-20, status=1, ipAttribution=)]
    2012-06-20 ylz8405

相关资讯

J Nuc Med:新疗法延长前列腺癌病人的生命

佛罗里达州迈阿密海滩——有已经扩散到骨的晚期肿瘤的前列腺癌病人的生存机会很差。参加美国核医学学会(Society of Nuclear Medicine)2012年会的科研人员说,一种新型放射性同位素疗法可能会让患这种病的病人活得更长。 骨骼系统是前列腺癌病人的第一位的转移部位。癌的骨转移发生在原发癌通过血液被输送到骨并且在那里发育的时候。这是一项对氯化镭-223或Ra-223的放射性同位素的I

JACC:血糖水平升高导致患心脏病风险增加

近日,一项哥本哈根大学的最新研究表明:血液中的葡萄糖水平增高会导致增加缺血性心脏病风险增高。这项研究涉及超过80,000人,研究论文发表在Journal of the American College of Cardiology杂志上。这项哥本哈根大学的新研究显示血糖略有升高对非糖尿病人罹患缺血性心脏病有一个更显著的风险。 研究团队对这些结果感到惊讶,因为到现在为止胆固醇被普遍认为是全球心脏健康

PLoS ONE:GPx3酶有助预防心血管疾病

近日,明尼苏达医学院的研究人员与公共卫生学院合作发现一种酶,该酶在较高水平以及高密度脂蛋白(好胆固醇)水平低时,可以大大降低风险心血管疾病。 这种新发现的酶叫谷胱甘肽过氧化物酶或GPX3,是一种天然抗氧化剂,有助于保护生物体的氧化损伤,有助于机体的自然修复。研究人员发现“好”胆固醇水平高的患者之间,GPX3酶的水平并没有显着性差异。然而,“好”胆固醇水平低的患者,GPX3酶可能对疾病来说是一个益

Mol Pharma:科学家揭示毛地黄可以抵御高血压和心力衰竭

近日,来自密歇根大学健康系统的研究者通过研究发现,一个使用了几个世纪的老药可以在机体的血管中激活一种机体保护机制。这种古老的心脏药物激发了中医的灵感,使得中医们使用这种药物来治疗处于瘟疫人群和过重人群。早在13世纪,有毒的草本植物毛地黄就被用于清理伤口,而且其干叶被用来酿酒以治疗因为心脏问题而导致的腿部肿胀。 这篇刊登在国际杂志Molecular Pharmacology上的研究文章中,研究者揭

Genetics:研究者揭示连接糖尿病和阿尔兹海默症的共同基因

近日,来自纽约城市大学的研究者研究发现,存在于阿尔茨海默症患者机体的基因可以影响其胰岛素途径。这个途径的破坏将会是引发糖尿病的一个标志,相关研究成果刊登在了近日的国际著名杂志Genetics上,这将为开发一些靶向治疗方法提供了线索和希望。 II型糖尿病患者存在高的痴呆风险,胰岛素途径介导了很多代谢过程,包括帮助维持神经系统的健康等等。目前尽管阿尔兹海默症的原因尚不清楚,但是目前患者死后诊断的标准

PLoS ONE:王福俤等人类代谢相关疾病离子组学研究获进展

近日,PLoS ONE在线发表了营养所王福俤研究组、林旭研究组及中科院系统生物学重点实验室李亦学研究组在代谢相关疾病离子组学方面的合作研究成果。 生物体内的离子(包括金属、类金属和非金属)含量及分布具有重要的生理学意义并逐渐成为生命科学的研究热点,离子组学是利用现代高通量元素分析手段如电感耦合等离子质谱(ICP-MS),结合生物信息学和功能基因组学等手段来研究检测样本中的离子含量、分布、转运代谢